Trial Profile
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 26 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Jul 2008 The expected completion date for this trial is now 1 Jan 2008.
- 21 Apr 2008 New trial record.